date,title,source
Oct-18-18,Intellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy,GlobeNewswire
Oct-29-18,Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer,GlobeNewswire
Oct-31-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Oct-31-18,Cambridge's Intellia delays gene editing trial,American City Business Journals
Oct-31-18,"Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-01-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-05-18,Here's Why CRISPR Stocks Fell as Much as 40.7% in October,Motley Fool
Nov-05-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-06-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-07-18,Cambridge's Editas asks FDA to start gene editing trial,American City Business Journals
Nov-07-18,Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT,Thomson Reuters StreetEvents
Nov-07-18,"Consolidated Research: 2018 Summary Expectations for STORE Capital, Ares Commercial Real Estate, Intellia Therapeutics, City Office REIT, RealPage, and Data I/O  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Nov-08-18,Intellia Therapeutics to Present at November Healthcare Investor Conferences,GlobeNewswire
Nov-26-18,"With genetically edited babies, a scientist transgresses a moral boundary",MarketWatch
Nov-26-18,Mass. biotech leaders voice alarm over report of first gene-edited babies,American City Business Journals
Nov-28-18,Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns',Benzinga
Nov-30-18,This Biotech Stock Could Launch Its First CRISPR Drug In 2022,Investor's Business Daily
Nov-30-18,Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018,Motley Fool
Nov-30-18,The Market is All Packed for Buenos Aires,Zacks
Dec-06-18,Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population,GlobeNewswire
Dec-10-18,Why CRSP Stock Has Added Layers of Risk,InvestorPlace
Dec-17-18,"New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Jan-04-19,These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy,Investor's Business Daily
Jan-07-19,"Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag",Zacks
Jan-10-19,"The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%",Motley Fool
Jan-11-19,Here's Why Intellia Therapeutics Stock Lost 23.8% in December,Motley Fool
